Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

39.67 +0.23 (+0.58%)
Official Closing Price Updated: 7:00 PM EDT, Aug 29, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
40 41 Next >
Top Research Reports For Apple, Lowe's & Shopify
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc., Lowe's Companies, Inc., and Shopify Inc., as well as two micro-cap stocks MIND Technology, Inc., and... 
Via Talk Markets
European Commission Faces Court Criticism Over COVID Vaccine Contract Transparency Ahead Of Vote on Ursula Von Der Leyen's Reappointment
European Commission faces scrutiny over COVID vaccine contract transparency ahead of key vote. Legal challenges and implications discussed. 
Via Benzinga
Is GSK a Top-Value Stock Right Now?
GSK, a multinational pharma company, scans as a bargain. 
Via The Motley Fool
3 Top Cancer Treatment Stocks to Buy Now
These cancer treatment stocks are well-positioned to benefit tremendously from strong demand for their cancer treatments in the longer term. 
Via InvestorPlace
Positive News is Driving This Cancer Drug Maker’s Stock Higher
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather 
Via MarketBeat
The 3 Most Undervalued Pharma Stocks to Buy in July 2024
Pharma stocks can be great investments during times of growth and recession, and are made even better if the stock is undervalued. 
Via InvestorPlace
Topics Economy
GSK Begins Shipping Influenza Vaccine Doses for 2024-25 Season
From GSK plc
Via Business Wire
3 Dirt-Cheap Drug Developers With Blockbuster Potential
These are three of the best cheap drug developer stocks for investors to keep an eye as their growth could be imminent. 
Via InvestorPlace
Health Officials Keep Close Eye On Bird Flu As It Infects Cows For The First Time
Avian influenza continues to spread among animals and has infected four dairy workers in the US. Concerns about human-to-human transmission are low. 
Via Benzinga
The 3 Most Undervalued Under-$50 Stocks to Buy in July 2024
A full-throated bull market makes it tough to find undervalued stocks under $50, but these three could soon lead the charge higher. 
Via InvestorPlace
Pfizer's RSV Vaccine Abrysvo Clears Concerns Over Preterm Birth Risk, Safety For Pregnant Women, New Study Shows
Pfizer's RSV vaccine, Abrysvo, for pregnant women shows no increased risk of pre-term births, according to a study. Researchers found no significant difference in pre-term birth rates between... 
Via Benzinga
United Kingdom Stocks, ETFs To Watch After Keir Starmer, Labour Party Win
New leadership in the United Kingdom could make several sectors standout going forward. Here's what experts are saying after the election. 
Via Benzinga
Topics ETFs
Upcoming Stock Spinoffs: Should You Pounce or Pass?
Stock spinoffs are a unique opportunity to pick up unloved, unwanted businesses but patience is often needed before buying in. 
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs. 
Via InvestorPlace
Topics Workforce
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK. 
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
3 No-Brainer Stocks to Buy With $300 Right Now for the Second Half of 2024
A modest amount of money can go a long way when it's put to work in highly innovative, game-changing businesses. 
Via The Motley Fool
Heartburn Drug Zantac Litigation: GSK And Other Pharma Giants Face Trial Over Cancer Claims
A Delaware judge dismissed GSK and other drugmakers' appeal, allowing over 70,000 lawsuits alleging Zantac causes cancer to proceed, with the companies needing Delaware Supreme Court approval to... 
Via Benzinga
Topics Lawsuit
CDC Advisor Panel Recommends RSV Shots In US For People Above 75 Years, Analyst Says Decision Negative For GSK
The CDC's ACIP recommends RSV vaccines for adults 75+, and for those 60-74 with chronic conditions. GSK's Arexvy is approved for adults 50-59 at risk. A decision on adults 50-59 is pending further... 
Via Benzinga
Why Is Moderna Stock Trading Lower On Wednesday?
The CDC's Advisory Committee on Immunization Practices is set to discuss recommendations for RSV, influenza, and COVID-19 vaccines. Moderna's data shows vaccine efficacy drops to 50% after 18 months in... 
Via Benzinga
Moderna Crumbles After RSV Vaccine Effectiveness Pales Vs. Pfizer, GSK Shots
After 18 months, Moderna's RSV vaccine proved about 50% effective against lower respiratory tract disease. 
Via Investor's Business Daily
Sanofi Looks To Sell $20B Icy Hot Division: Likely Bidders Include Advent, PAI Partners, Blackstone, CVC
Sanofi wants $20 billion for its consumer health division, attracting interest from major firms like Advent and PAI Partners. 
Via Benzinga
UK Chooses Pfizer Over GSK for Multi-Million Dose RSV Vaccine Contract
Pfizer secures a UK contract to supply millions of doses of its Abrysvo RSV vaccine, surpassing GSK's bid. The agreement includes doses for older adults and pregnant mothers. 
Via Benzinga
Industry Groups Back GSK's Effort To Halt 70,000 Lawsuits Associated With Heartburn Drug Zantac Caused Cancer
GSK, supported by major industry groups, seeks to stop 70,000 Zantac lawsuits in Delaware, arguing a recent court ruling threatens the state's business-friendly reputation and judicial consistency. 
Via Benzinga
Topics Lawsuit
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:GOVX),(NYSE:GSK),(NASDAQ:AZN),(NYSE:MRK) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Death
Analyst Projects Strong Growth for GSK-Innoviva Partnered Respiratory Drugs
Discover Cantor Fitzgerald's analysis on Innoviva, highlighting its unique royalty-based business model with GSK for asthma and COPD products. 
Via Benzinga
Pancreatic Cancer Market Is Projecting to Expand As NCI-Funded Research Expects to Empower Market Growth
From FN Media Group LLC
Via GlobeNewswire
7 A-Rated Biotech Stocks Worth Betting on in June
A-rated biotech stocks are highly coveted because they are at the forefront – or in the midst of -- groundbreaking innovation. 
Via InvestorPlace
3 Penny Stocks That Can Deliver Over 5,000% Upside by 2025: June Edition
Don’t miss out on these three penny stocks, which have amazing potential to take off following upcoming business developments this year. 
Via InvestorPlace
Moderna Says Combination Flu And Covid Vaccine Beat Out Rivals From Sanofi, GSK
If approved, this would be the first combination vaccine based on mRNA technology to hit the market. 
Via Investor's Business Daily
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
40 41 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.